Company: SMNR
Filing Date: 2025-08-08
Form Type: S-4/A
Source: 0001193125-25-177097
Chunk: 314

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-08
Form: S-4/A
Chunk 314
---
 Denali. After the completion of the IPO, Denali commenced an active search for prospective business combination targets and considered numerous potential target businesses with the objective of consummating its initial business combination. Representatives of Denali contacted, and were contacted by, numerous individuals and entities who presented potential business combination opportunities.

On January 25, 2023, Denali entered into the Longevity Merger Agreement, by and among Longevity, Holdco, Denali-Longevity Merger Sub, Longevity Merger Sub, and the Seller Representative. Pursuant to the Longevity Merger Agreement, the parties thereto intended to enter into the Longevity Business Combination, pursuant to which, among other things, immediately following the consummation of the acquisitions by Longevity of each of Cerevast Medical, Inc., Aegeria Soft Tissue LLC, and Novokera LLC, (i) the Denali-Longevity Merger would occur, with Denali as the surviving entity of the Denali-Longevity Merger, and (ii) the Longevity Merger would occur, with Longevity as the surviving company of the Longevity Merger. Afterwards, each of Longevity and Denali would be a subsidiary of Holdco, and Holdco would become a publicly traded company.

On January 9, 2024, Denali held the Longevity Business Combination Meeting and voted in favor of approving the Longevity Business Combination.

On May 13, 2024, according to Section 8.21 of the Longevity Merger Agreement, the Seller Representative informed Denali management that he received a written notice regarding the termination of one of the Cerevast Acquisition Agreement, the Aegeria Acquisition Agreement, and the Novokera Acquisition Agreement (each as defined in the Longevity Merger Agreement), with the possibility of rescinding the termination notice subject to the satisfaction of certain conditions. While the Longevity Agreement had not been formally terminated as of such date, Denali’s management was on notice of such possibility.

On May 30, 2024, Henry Ji, Ph.D., the Executive Chairperson of Semnur and Scilex, and Lei Huang, the Chief Executive Officer and a director of Denali and the Chief Executive Officer of US Tiger, were initially introduced by Jack Wu, a business partner of US Tiger, at the offices of US Tiger at 437 Madison Ave., New York.

During the meeting, Mr. Ji and Mr. Huang discussed if US Tiger could participate in Sc